Allianz Asset Management
SLDB icon

Allianz Asset Management’s Solid Biosciences SLDB Stock Holding History

Allianz Asset Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,100
Closed -$100K – 2263
2025
Q1 		$100K Buy
+27,100
New +$116K ﹤0.01% 2174

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Allianz Asset Management's SLDB Position: Q2 2025 in Review

Allianz Asset Management sold out of Solid Biosciences (SLDB) in Q2 2025, closing a stake of 27,100 shares — an estimated $100K sold.

Allianz Asset Management first reported a position in SLDB in Q1 2025 and held it in 1 quarter. The position peaked at $100K in Q1 2025. 114 funds tracked by Wall St. Rank hold SLDB as of Q2 2025.

  • Allianz Asset Management reported no remaining Solid Biosciences position as of Q2 2025 after selling out during the quarter.
  • Allianz Asset Management sold 27,100 Solid Biosciences shares in Q2 2025, an estimated $100K.
  • Allianz Asset Management first reported a position in Solid Biosciences in Q1 2025 and held it in 1 quarter.
  • Allianz Asset Management's Solid Biosciences position peaked at $100K in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2025.

Based on Allianz Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.